MicroStockProfit releases investment report on Oncothyreon

MicroStockProfit.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

Oncothyreon Inc. (ONTY) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. ONTY's lead product candidate is Stimuvax, which is a cancer vaccine in phase III development for non-small cell lung cancer (NSCLC). ONTY has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany, for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates consists of cancer vaccines and small molecule candidates. The Company's wholly owned subsidiaries include ONTY Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg. 

Message Board Search for ONTY: http://www.boardcentral.com/boards/ONTY

In the report, the analyst notes:

"ONTY recently reported a net loss of $0.8 million or $0.03 per basic and diluted share for the quarter ended March 31, 2010, compared with a net loss of $2.5 million or $0.13 per basic and diluted share for the comparable period in 2009. The decrease in net loss is primarily the result of a decrease in fair value of warrant liability of $4.6 million, offset by an increase in net loss from operations.  

"ONTY recently announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cancer (NSCLC), including the phase 3 START and INSPIRE trials. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees."

To read the entire report visit: www.microstockprofit.com/lp/ONTY